No Data
No Data
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets From Its Differentiated Research Platforms
Bristol-Myers Squibb (BMY): Hold Rating Justified by Mixed Growth Prospects and Pipeline Catalysts
Zenas BioPharma, Bicara Therapeutics Sets IPO Price Ranges as Summer Lull Ends
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
Zenas BioPharma Sets Price Range for $200 Million Initial Public Offering
No Data
RDK79 : Sorry, what’s a pdufa?
Xyno RDK79 : Prescription Drug User Fee Act, means FDA approval or rejection for a drug to go to market. One of the most important events to monitor if you are into pharma companies stock.
RDK79 Xyno : Thank you!
Tonyco : What site is that?